----item----
version: 1
id: {AEF20316-557C-4AAB-BCC7-D6A8928B374D}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/31/Dr Reddys To Market Amgen Therapies In India
parent: {41EBBC65-C73D-4320-B22C-6EBD0BE8A7D8}
name: Dr Reddys To Market Amgen Therapies In India
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 2418df56-4eef-4dcb-872c-1ec079b7cf85

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 45

Dr Reddy's To Market Amgen Therapies In India
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 44

Dr Reddys To Market Amgen Therapies In India
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2020

<p>Dr Reddy's Laboratories is to market and distribute three Amgen therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) on the Indian market.</p><p>The two other Amgen products that form part of the deal are Kyprolis (carfilzomib) and Blincyto (blinatumomab), the first approved bispecific CD19-directed CD3 T-cell engager. Dr Reddy's said it would execute a "full range" of regulatory and commercial services to seek approval and launch the products in India. </p><p>No indication of potential pricing plans was provided.</p><p>Dr Reddy's said that addressing unmet needs of patients in oncology and cardiovascular are key areas in India and, therefore, a priority for the company. It expects the collaboration to leverage both firms' capabilities &ndash; Amgen's innovative therapies with Dr Reddy's understanding of Indian patient and physician needs.</p><p>Repatha won <a href="http://www.scripintelligence.com/home/Surprise-as-Amgen-pips-RegeneronSanofi-to-first-PCSK9-inhibitor-approval-359541" target="_new">approval</a> in the EU in July and in the US its Prescription Drug User Fee Act action date is set at Aug. 27. </p><p>In July this year, the FDA approved <a href="http://www.scripintelligence.com/policyregulation/Amgen-wins-broader-use-of-Kyprolis-in-multiple-myeloma-359625" target="_new">broader use</a> of Kyprolis in multiple myeloma. </p><p>Amgen may also be on course to a <a href="http://www.scripintelligence.com/researchdevelopment/Amgens-Blincyto-on-path-to-broader-ALL-indication-359514" target="_new">broader indication</a> for Blincyto (blinatumomab) after top-line Phase II data looked positive in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor ALL. </p><p>Dr Reddy's, which has commercialized four biosimilars including rituximab and darbepoetin in emerging markets, has also filed US INDs for rituximab and Peg-GCSF. Its pipeline includes products such as trastuzumab and bevacizumab.</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 202

<p>Dr Reddy's Laboratories is to market and distribute three Amgen therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) on the Indian market.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 44

Dr Reddys To Market Amgen Therapies In India
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150731T130001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150731T130001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150731T130001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029444
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 45

Dr Reddy's To Market Amgen Therapies In India
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{FD7E3A1B-CD6C-4EA9-909E-043A9042A71F}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359717
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042432Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

2418df56-4eef-4dcb-872c-1ec079b7cf85
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042432Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
